Koehler Bryn, Ryoo Da Yeon, Krishna Somashekar G
Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Division of Gastroenterology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Diagnostics (Basel). 2023 Jan 17;13(3):344. doi: 10.3390/diagnostics13030344.
Pancreatic cystic lesions (PCLs) are known precursors to pancreatic cancer, one of the deadliest types of cancer worldwide. Surgical removal or pancreatectomies remain the central approach to managing precancerous high-risk PCLs. Endoscopic ultrasound (EUS)-guided therapeutic management of PCLs is a novel management strategy for patients with prohibitive surgical risks. Various ablation techniques have been explored in previous studies utilizing EUS-guided fine needle injection (FNI) of alcohol and chemotherapeutic agents. This review article focuses on EUS-FNI and chemoablation, encompassing the evolution of chemoablation, pancreatic cyst selection, chemotherapy drug selection, including novel agents, and a discussion of its safety and efficacy.
胰腺囊性病变（PCLs）是胰腺癌已知的癌前病变，胰腺癌是全球最致命的癌症类型之一。手术切除或胰腺切除术仍然是治疗癌前高危PCLs的主要方法。内镜超声（EUS）引导下的PCLs治疗管理是一种针对手术风险过高患者的新型管理策略。以往的研究利用EUS引导下的酒精和化疗药物细针注射（FNI）探索了各种消融技术。这篇综述文章聚焦于EUS-FNI和化学消融，涵盖化学消融的发展、胰腺囊肿的选择、化疗药物的选择（包括新型药物）以及对其安全性和有效性的讨论。
